{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=2",
    "query": {
      "condition": "Gene Expression",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T01:02:04.584Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00064727",
      "title": "Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Avandia (Rosiglitazone)",
          "type": "DRUG"
        },
        {
          "name": "Avanclia (Rosiqlitazone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2003-07-09",
      "completion_date": "2007-04-11",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064727"
    },
    {
      "nct_id": "NCT02179515",
      "title": "Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Breast Cancer",
        "Prostate Cancer",
        "Tumors (Others)",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "MVA-brachyury- TRICOM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 38,
      "start_date": "2014-06-28",
      "completion_date": "2018-02-28",
      "has_results": true,
      "last_update_posted_date": "2021-01-26",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02179515"
    },
    {
      "nct_id": "NCT00351559",
      "title": "IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Graft Rejection",
        "Heart Diseases"
      ],
      "interventions": [
        {
          "name": "AlloMap molecular expression testing",
          "type": "DEVICE"
        },
        {
          "name": "Right ventricular endomyocardial biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "XDx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 629,
      "start_date": "2005-01",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2009-11-20",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 13,
      "location_summary": "Palo Alto, California • Stanford, California • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00351559"
    },
    {
      "nct_id": "NCT01901679",
      "title": "Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Celebrex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 70 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2013-07",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01901679"
    },
    {
      "nct_id": "NCT02352948",
      "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non - Small Cell Lung Cancer NSCLC"
      ],
      "interventions": [
        {
          "name": "MEDI4736 (durvalumab)",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)",
          "type": "DRUG"
        },
        {
          "name": "tremelimumab (anti-CTLA4)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 597,
      "start_date": "2015-01-13",
      "completion_date": "2023-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 33,
      "location_summary": "Chandler, Arizona • Anaheim, California • Duarte, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02352948"
    },
    {
      "nct_id": "NCT00479674",
      "title": "Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abraxane",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2007-05",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-02-18",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 4,
      "location_summary": "Charlotte, North Carolina • Concord, North Carolina • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Concord",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00479674"
    },
    {
      "nct_id": "NCT00047996",
      "title": "Blood Collection for Research Related to Certain Diseases Involving Blood Vessels",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2002-11-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Fairfax, Virginia",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047996"
    },
    {
      "nct_id": "NCT00186368",
      "title": "Microarray Analysis of Gene Expression in Prostate Tissues",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 867,
      "start_date": "1999-04-06",
      "completion_date": "2009-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186368"
    },
    {
      "nct_id": "NCT04492579",
      "title": "Newborns Supplemented With Gentle-UHT Donor Milk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Newborns",
        "Breast Milk Expression"
      ],
      "interventions": [
        {
          "name": "Gentle-UHT donor human milk supplementation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "LactaLogics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "4 Days",
        "sex": "ALL",
        "summary": "Up to 4 Days"
      },
      "enrollment_count": 31,
      "start_date": "2018-08-03",
      "completion_date": "2020-01-17",
      "has_results": false,
      "last_update_posted_date": "2020-07-30",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 1,
      "location_summary": "Port Saint Lucie, Florida",
      "locations": [
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492579"
    },
    {
      "nct_id": "NCT03194698",
      "title": "Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ocular Rosacea",
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Intense Pulsed Light Treatment (IPL)",
          "type": "DEVICE"
        },
        {
          "name": "Meibomian Gland Expression",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 20,
      "start_date": "2017-08-17",
      "completion_date": "2018-12-06",
      "has_results": true,
      "last_update_posted_date": "2020-01-03",
      "last_synced_at": "2026-07-23T01:02:04.584Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03194698"
    }
  ]
}